Earnings Releases·Nov 13, 2026, 7:50 AM ET

TuHURA Biosciences — Third Quarter 2026 Earnings Summary

R&D expenses decreased 26% year-over-year to $3.7 million driven by lower manufacturing costs, while G&A expenses rose 25% to $2.0 million due to stock compensation and public company costs; net cash outflows from operations improved to $18.1 million for the nine months ended September 30, 2026, compared to $22.1 million in the prior year period.
Secured $9.2 million in gross proceeds from the Parkview credit facility, bringing total cash and cash equivalents to $1.9 million as of September 30, 2026, with management noting the $50 million facility provides non-dilutive funding to reach value-creating milestones.
IFx-2.0 demonstrated durable anti-tumor responses in the first three patients of a first-line MCC study; TBS-2025 received FDA "Study May Proceed" notice for a Phase 1b trial in mutNPM1 AML, while new patents were granted extending coverage for TBS-2025 to 2042 and DOR ADC technology to 2043.
Future outlook includes receiving orphan drug designation for IFx-2.0 in MCC in H2 2026, initiating TBS-2025 Phase 1b/2 trials in H2 2026, and presenting DOR inhibitor data at the ASH Annual Meeting in December.